Multiple myeloma registry study
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study collects information from multiple myeloma patients who previously took part in a GMMG therapy study. It helps researchers learn more about the disease and treatments over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in a past GMMG therapy study for multiple myeloma.
- You cannot have organ amyloidosis at the time of diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial enrolls people with multiple myeloma who are starting (or have recently started) standard drug treatment, so researchers can collect real-world information about patients’ experiences and outcomes. It may help by improving future care planning and study designs, while adding an extra set of questionnaires to your routine.
This study looks at how patients with multiple myeloma are doing over time and what factors might affect their health. The goal is to learn more about the disease and improve care.
This is a study that collects information from people diagnosed with multiple myeloma. It may help researchers understand the disease and improve future care by using past and ongoing patient data.
This study creates a real-world registry (a group database) of people with active, symptomatic multiple myeloma. It helps researchers learn from patients and doctors over time and may support future research and treatment improvements.
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
This trial tests a new drug, BMS-986453, for people newly diagnosed with multiple myeloma. It aims to see if the drug is safe and works well for those who cannot or choose not to have a stem cell transplant.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.